Trade Vitrolife - VITR CFD

Trading Conditions

• Type: CFD
• Spread: 0.8
• Long position overnight funding adjustment: -0.01565%
• Short position overnight funding adjustment: -0.00657%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: SEK
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Sweden
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 93.8
• Open: 97.6
• 1-Year Change: -35.87%
• Day's Range: 95 - 97.6

Trade Vitrolife - VITR CFD

About Vitrolife AB

Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vitrolife AB revenues increased 35% to SEK1.68B. Net income applicable to common stockholders increased 19% to SEK341M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share remained flat at SEK0.80. Basic Earnings per Share excluding Extraordinary Items increased from SEK2.64 to SEK2.97.

Equity composition

1999: Stock Split in the ratio 1:2. 5/2018, 5-for-1 stock split (Factor: 5).